This document is an update of the British Sarcoma Group guidelines (2016) and provides a
reference standard for the clinical care of UK patients with primary malignant bone tumours …

Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour,
occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of …

Highlights•This Clinical Practice Guideline provides key recommendations on the
management of bone sarcomas.•Recommendations have been agreed following a …

Background: Recent clinical studies have suggested that denosumab is associated with
tumor response and reduced surgical morbidity in patients with giant-cell tumor of bone …

Simple Summary According to the 2020 World Health Organization classification, a giant cell
tumor of bone is an intermediate malignant bone tumor. Denosumab treatment before …

Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor
of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is …

Background Giant cell tumour of the bone (GCTB) is an aggressive osteolytic primary
tumour. GCTB is rich in osteoclast-like giant cells and contains mononuclear cells that …

The heterogeneity of sarcomas with regard to molecular genesis, histology, clinical
characteristics, and response to treatment makes management of these rare yet diverse …

Background Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely
metastazing bone tumor. This is a retrospective study evaluating a large series of GCTB …

Background Denosumab is a human monoclonal antibody (mAb) that specifically inhibits
tumor-associated bone lysis through the RANKL pathway and has been used as …